Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I randomized double-blind placebo-controlled study of subcutaneous BIM23B065 in healthy men
NL-OMON41949Phase 1Active, not recruiting
- Sponsor
- Centre for Human Drug Research
- Start
- Mar 2015
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in acromegaly comparing BIM23B065 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Mar 2015; status: active, not recruiting.
02
Drugs
BIM23B065
03
Conditions
acromegaly
Beyond the preview
Go deeper on NL-OMON41949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41949.